Intercept Pharmaceuticals, Inc. (ICPT): Price and Financial Metrics

Intercept Pharmaceuticals, Inc. (ICPT): $12.12

0.15 (+1.25%)

POWR Rating

Component Grades








Add ICPT to Watchlist
Sign Up

Industry: Biotech




#54 of 382

in industry

ICPT Price/Volume Stats

Current price $12.12 52-week high $21.86
Prev. close $11.97 52-week low $8.82
Day low $11.92 Volume 187,233
Day high $12.22 Avg. volume 1,004,872
50-day MA $14.61 Dividend yield N/A
200-day MA $15.68 Market Cap 505.25M

ICPT Stock Price Chart Interactive Chart >


  • Value is the dimension where ICPT ranks best; there it ranks ahead of 93.48% of US stocks.
  • ICPT's strongest trending metric is Growth; it's been moving down over the last 179 days.
  • ICPT ranks lowest in Sentiment; there it ranks in the 0th percentile.

ICPT Stock Summary

  • With a price/earnings ratio of 1.85, INTERCEPT PHARMACEUTICALS INC P/E ratio is greater than that of about just 2.52% of stocks in our set with positive earnings.
  • ICPT's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 1.23% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, INTERCEPT PHARMACEUTICALS INC is reporting a growth rate of -1,244.34%; that's higher than merely 1.52% of US stocks.
  • Stocks that are quantitatively similar to ICPT, based on their financial statements, market capitalization, and price volatility, are STX, INSG, GDDY, KPTI, and THTX.
  • ICPT's SEC filings can be seen here. And to visit INTERCEPT PHARMACEUTICALS INC's official web site, go to

ICPT Valuation Summary

  • In comparison to the median Healthcare stock, ICPT's price/sales ratio is 74.51% lower, now standing at 1.3.
  • Over the past 129 months, ICPT's EV/EBIT ratio has gone up 22.7.

Below are key valuation metrics over time for ICPT.

Stock Date P/S P/B P/E EV/EBIT
ICPT 2023-05-23 1.3 5.8 1.9 3.0
ICPT 2023-05-22 1.3 5.9 1.9 3.0
ICPT 2023-05-19 1.9 8.4 2.7 3.7
ICPT 2023-05-18 1.9 8.4 2.7 3.7
ICPT 2023-05-17 2.0 8.6 2.8 3.8
ICPT 2023-05-16 2.3 10.1 3.3 4.2

ICPT Growth Metrics

    Its 4 year net income to common stockholders growth rate is now at 7.63%.
  • Its 4 year revenue growth rate is now at 497.99%.
  • The 4 year cash and equivalents growth rate now stands at -30.67%.
ICPT's revenue has moved up $78,329,000 over the prior 33 months.

The table below shows ICPT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 330.331 -18.121 206.361
2022-06-30 345.57 3.106 -64.724
2022-03-31 370.389 -7.113 -68.29
2021-12-31 363.468 -41.639 -91.426
2021-09-30 354.332 -61.467 -107.293
2021-06-30 341.026 -106.584 -170.13

ICPT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ICPT has a Quality Grade of B, ranking ahead of 77.14% of graded US stocks.
  • ICPT's asset turnover comes in at 0.66 -- ranking 47th of 682 Pharmaceutical Products stocks.
  • GBT, AVDL, and SYRS are the stocks whose asset turnover ratios are most correlated with ICPT.

The table below shows ICPT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.660 0.992 -0.066
2021-06-30 0.616 0.988 -0.139
2021-03-31 0.552 0.984 -0.191
2020-12-31 0.506 0.983 -0.239
2020-09-30 0.455 0.977 -0.277
2020-06-30 0.397 0.980 -0.282

ICPT Price Target

For more insight on analysts targets of ICPT, see our ICPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $31.63 Average Broker Recommendation 1.92 (Hold)

Intercept Pharmaceuticals, Inc. (ICPT) Company Bio

Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic underserved liver diseases. The company was founded in 2002 and is based in New York, New York.

ICPT Latest News Stream

Event/Time News Detail
Loading, please wait...

ICPT Latest Social Stream

Loading social stream, please wait...

View Full ICPT Social Stream

Latest ICPT News From Around the Web

Below are the latest news stories about INTERCEPT PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ICPT as an investment opportunity.

Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Shift From Loss To Profit

We feel now is a pretty good time to analyse Intercept Pharmaceuticals, Inc.'s ( NASDAQ:ICPT ) business as it appears...

Yahoo | June 1, 2023

Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Jefferies Healthcare Conference June 7-8, 2023

MORRISTOWN, N.J., May 31, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will be participating in investor meetings at the Jefferies Healthcare Conference at the Marriott Marquis in New York City on June 7-8, 2023. Meeting Details For investors attending the conference who wish to meet with the Intercep

Yahoo | May 31, 2023

Biotech Stock Roundup: IRWD Announces Buyout, ICPT, SRPT & PTCT Fall on Updates

Regulatory and pipeline updates from Intercept (ICPT) and Sarepta (SRPT) lead to a decline in the share price of both companies.

Yahoo | May 25, 2023

Why Madrigal Pharmaceuticals Stock Is Marching Higher Today

Shares of the clinical-stage drugmaker Madrigal Pharmaceuticals (NASDAQ: MDGL) were up by 6.2% on elevated volume as of 12:16 p.m. ET Wednesday. The biotech appears to be benefiting from two key tailwinds. First, a Food and Drug Administration (FDA) panel voted overwhelmingly last Friday against approving Intercept Pharmaceuticals' (NASDAQ: ICPT) candidate, obeticholic acid, for treating pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis (NASH).

Yahoo | May 24, 2023

4 big analyst cuts: Apple loses buy rating on slack iPhone demand

Here is your Pro Recap of the biggest analyst cuts you may have missed since yesterday: downgrades for Apple, Revolve, Rain Therapeutics, and Intercept Pharmaceuticals. Loop Capital downgraded Apple (NASDAQ:AAPL) to Hold from Buy with a price target of $180.00. The firm sees a material downside risk to revenue (both iPhone and overall) estimates for Q3, relative to both the company’s guidance and Street forecasts.

Yahoo | May 23, 2023

Read More 'ICPT' Stories Here

ICPT Price Returns

1-mo -23.15%
3-mo -24.81%
6-mo -17.44%
1-year -13.12%
3-year -85.28%
5-year -84.09%
YTD -2.02%
2022 -24.06%
2021 -34.05%
2020 -80.07%
2019 22.95%
2018 72.53%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!